Literature DB >> 18037415

Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes.

Luca Malcovati1.   

Abstract

Transfusion dependency is an independent prognostic factor in myelodysplastic syndromes (MDS). The detrimental effect on survival is related to the severity of transfusion requirement and is more noticeable in low-risk patients. Elevated serum ferritin levels have a poor prognostic impact on the survival of transfusion-dependent patients with refractory anemias, and can adversely affect the outcome of patients with MDS receiving allogeneic stem-cell transplantation. Sequential measurements of serum ferritin are useful for measuring secondary iron overload in MDS patients. The implementation of non-invasive methods for assessing tissue iron and organ function should clarify the impact of iron-mediated organ damage on patients with MDS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18037415     DOI: 10.1016/S0145-2126(07)70459-9

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  27 in total

1.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

Review 2.  Iron chelation therapy in myelodysplastic syndromes: where do we stand?

Authors:  Mhairi Mitchell; Steven D Gore; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2013-08       Impact factor: 2.929

3.  Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Franklin Hendrick; Erika Friedmann; Maria R Baer; Steven D Gore; Medha Sasane; Carole Paley; Amy J Davidoff
Journal:  J Comp Eff Res       Date:  2015-08       Impact factor: 1.744

Review 4.  New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?

Authors:  Alberto Grossi; Giancarlo Maria Liumbruno
Journal:  Blood Transfus       Date:  2008-10       Impact factor: 3.443

5.  A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy.

Authors:  D Sanford; C C Hsia
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

6.  Kinetics of iron removal by phlebotomy in patients with iron overload after allogeneic hematopoietic cell transplantation.

Authors:  Ann-Kathrin Eisfeld; Rainer Krahl; Nadja Jaekel; Dietger Niederwieser; Haifa Kathrin Al-Ali
Journal:  Am J Blood Res       Date:  2012-11-25

Review 7.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review.

Authors:  Rebecca L C Adams; Robert J Bird
Journal:  Ther Adv Hematol       Date:  2013-04

9.  Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: results from a multicentre, observational study.

Authors:  Joan Cid; Luis Palomera; Matías Díaz; Concha Zamora; Fernando Solano
Journal:  Blood Transfus       Date:  2013-03-14       Impact factor: 3.443

10.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.